Literature DB >> 1832817

GM2-gangliosidosis B1 variant: analysis of beta-hexosaminidase alpha gene mutations in 11 patients from a defined region in Portugal.

M R dos Santos1, A Tanaka, M C sá Miranda, M G Ribeiro, M Maia, K Suzuki.   

Abstract

The GM2-gangliosidosis B1 variant occurs at an exceptionally high frequency in the northern part of Portugal. In most patients, the disease manifests itself as a juvenile form, as opposed to the late-infantile form described for many patients from other parts of the world. We have analyzed the beta-hexosaminidase alpha gene in 11 patients, as well as in some relatives, in order to characterize the underlying abnormalities. They were screened for the two previously identified mutations responsible for the B1 variant phenotype (G533----A, also designated as the "DN allele," and C532---T) by PCR amplification of an 800-bp DNA fragment and subsequent dot-blot hybridization with allele-specific oligonucleotides. The fragment amplified from one patient was also subcloned and sequenced. Ten patients, constituting a clinically and biochemically homogeneous group, were found to be homozygous for the DN allele. The other, whose clinical profile more resembled the late-infantile phenotype often described in the literature, was a compound heterozygote carrying the DN allele and another, as yet unidentified, abnormal allele. Our results, corroborated by previously published data, suggest that homozygotes and compound heterozygotes for the DN allele may be distinguishable at the phenotypic level, depending on the nature of the abnormality in the other allele. A common ancestral origin for the DN allele can also be postulated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1832817      PMCID: PMC1683169     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  7 in total

1.  Mutation in GM2-gangliosidosis B1 variant.

Authors:  K Ohno; K Suzuki
Journal:  J Neurochem       Date:  1988-01       Impact factor: 5.372

2.  Buffer gradient gels and 35S label as an aid to rapid DNA sequence determination.

Authors:  M D Biggin; T J Gibson; G F Hong
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

3.  GM2-gangliosidosis B1 variant: analysis of beta-hexosaminidase alpha gene abnormalities in seven patients.

Authors:  A Tanaka; K Ohno; K Sandhoff; I Maire; E H Kolodny; A Brown; K Suzuki
Journal:  Am J Hum Genet       Date:  1990-02       Impact factor: 11.025

Review 4.  Juvenile GM2 gangliosidosis variant B1: clinical and biochemical study in seven patients.

Authors:  M Maia; D Alves; G Ribeiro; R Pinto; M C Sa Miranda
Journal:  Neuropediatrics       Date:  1990-02       Impact factor: 1.947

5.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

6.  GM2-gangliosidosis B1 variant: a wide geographic and ethnic distribution of the specific beta-hexosaminidase alpha chain mutation originally identified in a Puerto Rican patient.

Authors:  A Tanaka; K Ohno; K Suzuki
Journal:  Biochem Biophys Res Commun       Date:  1988-10-31       Impact factor: 3.575

7.  Variant of GM2-gangliosidosis with hexosaminidase A having a severely changed substrate specificity.

Authors:  H J Kytzia; U Hinrichs; I Maire; K Suzuki; K Sandhoff
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

  7 in total
  10 in total

1.  Structural basis of the GM2 gangliosidosis B variant.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hitoshi Sakuraba; Hoang Thi Ngoc Lan; Akemi Tanaka; Kousaku Ohno; Yuko Sugimoto; Haruaki Ninomiya; Hirofumi Doi
Journal:  J Hum Genet       Date:  2003-10-24       Impact factor: 3.172

2.  Clinical, enzymatic, and molecular characterisation of a Portuguese family with a chronic form of GM2-gangliosidosis B1 variant.

Authors:  M G Ribeiro; T Sonin; R A Pinto; A Fontes; H Ribeiro; E Pinto; M M Palmeira; M C Sá Miranda
Journal:  J Med Genet       Date:  1996-04       Impact factor: 6.318

Review 3.  The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.

Authors:  Gustavo H B Maegawa; Tracy Stockley; Michael Tropak; Brenda Banwell; Susan Blaser; Fernando Kok; Roberto Giugliani; Don Mahuran; Joe T R Clarke
Journal:  Pediatrics       Date:  2006-10-02       Impact factor: 7.124

4.  Molecular genetics of Tay-Sachs disease in Japan.

Authors:  A Tanaka; H Sakazaki; H Murakami; G Isshiki; K Suzuki
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

5.  Identification of GM2-gangliosidosis B1 variant carriers.

Authors:  M G Ribeiro; R Pinto; P Oliveira; M C Sá Miranda
Journal:  J Inherit Metab Dis       Date:  1993       Impact factor: 4.982

6.  Mutation analysis of a Sandhoff disease patient in the Maronite community in Cyprus.

Authors:  Y Hara; P Ioannou; A Drousiotou; G Stylianidou; V Anastasiadou; K Suzuki
Journal:  Hum Genet       Date:  1994-08       Impact factor: 4.132

7.  Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.

Authors:  M Joanne Lemieux; Brian L Mark; Maia M Cherney; Stephen G Withers; Don J Mahuran; Michael N G James
Journal:  J Mol Biol       Date:  2006-04-27       Impact factor: 5.469

8.  Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.

Authors:  Brian L Mark; Don J Mahuran; Maia M Cherney; Dalian Zhao; Spencer Knapp; Michael N G James
Journal:  J Mol Biol       Date:  2003-04-11       Impact factor: 5.469

9.  Utility of Gene Panels for the Diagnosis of Inborn Errors of Metabolism in a Metabolic Reference Center.

Authors:  Sofia Barbosa-Gouveia; María E Vázquez-Mosquera; Emiliano González-Vioque; José V Álvarez; Roi Chans; Francisco Laranjeira; Esmeralda Martins; Ana Cristina Ferreira; Alejandro Avila-Alvarez; María L Couce
Journal:  Genes (Basel)       Date:  2021-08-19       Impact factor: 4.096

10.  Deletion of arginine (608) in acid sphingomyelinase is the prevalent mutation among Niemann-Pick disease type B patients from northern Africa.

Authors:  M T Vanier; K Ferlinz; R Rousson; S Duthel; P Louisot; K Sandhoff; K Suzuki
Journal:  Hum Genet       Date:  1993-10       Impact factor: 4.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.